<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157923">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01718093</url>
  </required_header>
  <id_info>
    <org_study_id>H-29924</org_study_id>
    <secondary_id>DK096067</secondary_id>
    <nct_id>NCT01718093</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes</brief_title>
  <official_title>A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if the use of metformin and sitagliptin used in
      conjunction with insulin can improve the blood sugars of teenagers with Type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The study will include a total of 4 visits. The time period between the very first
           visit and the very last visit will be between 10 and 15 weeks. Each participant will be
           randomized to one of the 3 groups in the study. The groups are as follows:

        -  Group 1: Insulin and sitagliptin

        -  Group 2: Insulin and metformin

        -  Group 3: Insulin and combination of sitagliptin and metformin

        -  The study is a randomized open label design. All subjects will undergo a screening
           visit; if inclusion and exclusion criteria are fulfilled they will be enrolled in the
           study. At the time of enrollment the subject will continue their home insulin regimen
           and will be randomized to an add an oral hypoglycemic agent(s) : metformin, sitagliptin
           or combination therapy (metformin and sitagliptin). The total duration on study
           medication will be 6 weeks. All subjects will undergo a baseline mixed meal tolerance
           test (MMTT) in their standard or usual insulin Each subject will undergo a total of two
           studies. Blood draws will be necessary.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To determine the glucose lowering effect of metformin and sitagliptin alone and as combination therapy when used as adjuncts to insulin in adolescents with T1DM.</measure>
    <time_frame>10 - 15 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Insulin plus sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin plus metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin plus sitagliptin and metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>up to 50 mg twice a day</description>
    <arm_group_label>Insulin plus sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>up to 1000 mg twice a day</description>
    <arm_group_label>Insulin plus metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin + Metformin</intervention_name>
    <description>up to 50/1000 mg twice a day</description>
    <arm_group_label>Insulin plus sitagliptin and metformin</arm_group_label>
    <other_name>Sitagliptin + Metformin = Janumet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 13 to 18 years

          -  HbA1c &gt;7.5% but &lt;10%

          -  Subjects must be on intensive insulin management

          -  Tanner stage greater than or equal to 4

          -  Must have T1DM for at least one year , T1DM defined by ADA criteria and having at
             least one of the following antibodies: Anti-GAD, Anti-islet, Anti-insulin

          -  C-peptide &gt; 0.6 ng/ml

        Exclusion Criteria:

          -  Type 2 diabetes

          -  History of any other chronic condition (except hypothyroidism stable on medications)

          -  Actively taking medications that may affect glucose excursions (steroids or oral
             contraceptives)

          -  Evidence of anemia, clinically significant elevation of the liver enzymes (3 X
             normal), amylase or lipase (2 X normal), abnormal triclycerides (3 X normal),
             abnormal renal function test

          -  An unsupportive family environment and pregnant or lactating females
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luisa M. Rodriguez, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathy Shippy, RN, CCRP</last_name>
    <phone>832-824-1268</phone>
    <email>klshippy@texaschildrens.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Shippy, RN, CCRP</last_name>
      <phone>832-824-1268</phone>
      <email>klshippy@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Luisa Rodriguez, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Velez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bonnie Goldsmith, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Morey W. Haymond, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria J. Redondo, MD, PhD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shannon French, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>October 29, 2012</lastchanged_date>
  <firstreceived_date>October 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Luisa M. Rodriguez</investigator_full_name>
    <investigator_title>Assistant Professor - Department of Pediatrics - Endocrinology and Metabolism</investigator_title>
  </responsible_party>
  <keyword>Adolescents</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sitagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
